Dermatology

Our top dermatology content of 2025 highlights AI wearables, new biologics, emerging vitiligo treatments, and strategies for rare and complex skin diseases.

Alopecia areata significantly impacts quality of life, driven by appearance-related anxiety related to where hair loss occurs more than how much is lost.

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, affordability of classic therapies, and advancing AI in dermatology.

A phase 2b trial found vixarelimab rapidly reduced itch and lesion burden in prurigo nodularis, with sustained benefit and a favorable safety profile.

A study using Mendelian randomization found higher BMI and IBD have causal links to hidradenitis suppurativa risk.

Pediatric atopic dermatitis advances, ruxolitinib safety, IgE insights, and more at the Society for Pediatric Dermatology (SPD) 2025 meeting.

Polarized dermatoscopes produced higher-quality teledermatology images but at greater cost, raising questions about feasibility and equitable access.

Phase 3 ADORING data show tapinarof improves skin, itch, and sleep in children with atopic dermatitis, with similar efficacy and safety in those with comorbidities.

Phase 3 ADORING data show tapinarof cream delivers early, consistent skin, itch, and sleep improvements in children with atopic dermatitis, with low adverse event rates.

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

Despite advances, Arielle Kauvar, MD, calls for more research on laser and energy-based devices for patients with skin of color.

Colorblind energy devices and long-wavelength lasers are safest for darker skin, says Ariella Kauvar, MD, with a thorough patient history and physical exam key to preventing complications.

Arielle Kauvar, MD, says pre- and post-treatment care helps prevent hyperpigmentation and complications from laser procedures for all skin types, including skin of color.

Experts discussed safe and effective management strategies for patients with hidradenitis suppurativa at the 2025 Skin of Color Update.

Eliot F. Battle, MD, discusses how to effectively and successfully treat skin of color.

Jenifer Soung, MD, fo Southern California Dermatology, discussed how glucagon-like peptide-1 receptor agonists aid in treating patients with psoriatic disease.

Eliot F. Battle, MD, discusses the art of using lasers and energy-based technology to treat patients with skin of color.

Experts at the Skin of Color Update highlighted the potential benefits of GLP-1 RAs in managing obesity, as well as psoriasis and hidradenitis suppurativa symptom management.

FDA approvals since the last Skin of Color Update expand topical and biologic options for various dermatological conditions, benefiting patients with skin of color.

Oral upadacitinib combined with topical ruxolitinib cream may be a promising therapeutic approach for patients with progressive nonsegmental vitiligo.

The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.

Oral nicotinamide reduced the risk of new skin cancers—especially squamous cell carcinoma—by up to 54% when started after a first diagnosis.